Yinghao Sun

TL;DR: Treatment of sunitinib-resistant RCC with locked nucleic acids targeting lncARSR or an AXL/c-MET inhibitor restored sunit inib response and may serve as a predictor and a potential therapeutic target for sun itinib resistance.

TL;DR: It is shown that PD-L1 protein abundance is regulated by cyclin D–CDK4 and the cullin 3–SPOP E3 ligase via proteasome-mediated degradation, which reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1–PD-L 1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.

TL;DR: A comprehensive landscape of the transcriptome profiles of 14 primary prostate cancers and their paired normal counterparts from the Chinese population using RNA-seq reveals tremendous diversity across prostate cancer transcriptomes with respect to gene fusions, long noncoding RNAs (long ncRNA), alternative splicing and somatic mutations.

TL;DR: In this article, the role of MALAT-1 in prostate cancer was investigated and the therapeutic effects of siRNA-targeting on castration resistant prostate cancer cells in vitro and in vivo.

TL;DR: Genome-wide profiling revealed that MALAT-1 and prostate cancer gene 3 (PCA3) are overexpressed in PCa tissues and MD-miniRNA can be used as a novel plasma-based biomarker for PCa detection and can improve diagnostic accuracy by predicting prostate biopsy outcomes.